Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
-
Publication number: 20140193347Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: September 4, 2013Publication date: July 10, 2014Applicant: CAMURUS ABInventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Patent number: 8771740Abstract: Nanoparticles of a compound are produced by spraying a solution of the compound into a heated chamber. The resulting product comprises a free flowing mixture of nanoparticles of the compound.Type: GrantFiled: May 21, 2006Date of Patent: July 8, 2014Inventor: Nicholas J. Kerkhof
-
Publication number: 20140187481Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: ApplicationFiled: July 3, 2013Publication date: July 3, 2014Inventors: Arthur Tudor Tucker, Nigel Benjamin
-
Publication number: 20140178466Abstract: Provided herein are steroid containing composition suitable for providing therapeutically effective amount of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Publication number: 20140179652Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh V. Patel, Srinivasan Venkateshwaran
-
Patent number: 8759329Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 24, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140171918Abstract: Embodiments herein are directed to methods for increasing testosterone levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of testosterone by needle-free injection to an injection site. Some embodiments are further directed to a method of increasing testosterone levels in a subject in need thereof, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of testosterone and a pharmaceutically acceptable carrier by needle-free injection. Some embodiments are directed to a method of minimizing fluctuations in testosterone levels in a subject diagnosed with hypogonadism, comprising serially administering to the subject a therapeutically effective amount of testosterone by needle-free injection to an injection site.Type: ApplicationFiled: December 13, 2013Publication date: June 19, 2014Applicant: Bioject, Inc.Inventor: Mark A. LOGOMASINI
-
Patent number: 8754070Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 17, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8748402Abstract: Provided by the present invention are compositions or formulations suitable for application to a patient's eyes which utilizes a topical ophthalmically-acceptable formulation comprising a therapeutically-effective amount of an ophthalmically-active antimicrobial agent, and an ophthalmically-active anti-inflammatory or steroidal agent in combination with physiologic levels of serum electrolytes in an ophthalmic formulation for the treatment of changes in the normal eye condition. The invention also includes methods of treating patient's having an ophthalmic disease, injury or disorder, utilizing the compositions or formulations. Also provided are kits comprising the compositions or formulations and a means of applying the compositions or formulation to the patient's eyes.Type: GrantFiled: February 9, 2012Date of Patent: June 10, 2014Assignee: Bausch & Lomb Pharma Holdings Corp.Inventors: Mark Abelson, Kirk McMullin, Angel Padilla
-
Patent number: 8741881Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: June 3, 2014Assignees: Unimed Pharmaceuticals, LLC, Besins Healthcare Luxembourg, SARLInventors: Ramana Malladi, Jodi Stahlman
-
Publication number: 20140142076Abstract: This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.Type: ApplicationFiled: November 14, 2013Publication date: May 22, 2014Applicant: ABON PHARMACEUTICALS, LLCInventors: Salah U. AHMED, Yanming ZU, Karunakar NEELAM, Saad MUNTAZIM, Tahseen A. CHOWDHURY, Shiying TIAN
-
Patent number: 8729057Abstract: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.Type: GrantFiled: March 14, 2013Date of Patent: May 20, 2014Assignees: Unimed Pharmaeuticals, LLC, Besins Healthcare Luxembourg SARLInventors: Ramana Malladi, Jodi Stahlman
-
Patent number: 8722652Abstract: Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3?]-androsta-4,16-dien-3-ol.Type: GrantFiled: August 13, 2012Date of Patent: May 13, 2014Assignee: Pherin Pharmaceuticals, Inc.Inventor: Louis Monti-Bloch
-
Patent number: 8722653Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.Type: GrantFiled: September 19, 2012Date of Patent: May 13, 2014Assignees: Laboratoire HRA-Pharma, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
-
Patent number: 8703169Abstract: The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same.Type: GrantFiled: August 8, 2007Date of Patent: April 22, 2014Assignee: Abbott Cardiovascular Systems Inc.Inventor: Jeong Lee
-
Patent number: 8697678Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.Type: GrantFiled: January 19, 2011Date of Patent: April 15, 2014Assignee: Drawbridge Pharmaceuticals Pty LtdInventors: Juliet Marguerite Goodchild, Colin Stanley Goodchild, Benjamin James Boyd
-
Publication number: 20140088053Abstract: The present application discloses 17? hydroxy steroid dehydrogenase (17? HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17? HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17? HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17? HSD1 and 17? HSD3 that have a spiro-morpholine substituent at C20.Type: ApplicationFiled: March 26, 2012Publication date: March 27, 2014Applicant: UNIVERSITÉ LAVALInventors: Donald Poirier, René Maltais, Jenny Roy
-
Publication number: 20140080769Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Applicants: The Chancellor, Masters and Scholars of the University of Oxford, The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: Frances Mary Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
-
Publication number: 20140073618Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.Type: ApplicationFiled: July 12, 2012Publication date: March 13, 2014Inventor: Claudia MATTERN
-
Patent number: 8664210Abstract: New aminooxime derivatives at position 3 of 2- and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described in detail in the application.Type: GrantFiled: September 18, 2008Date of Patent: March 4, 2014Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Alberto Cerri, Giuseppe Bianchi, Giorgio Fedrizzi, Patrizia Ferrari, Mauro Gobbini, Marco Torri, Giuseppe Marazzi, Walter Cabri
-
Publication number: 20140056851Abstract: The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal preventing a reduction in energy metabolism by an animal reducing the risk of regaining weight by an animal after weight loss, and ameliorating undesirable animal behaviors associated with reduced caloric intake by intermittently feeding an animal a first diet containing calories that meet the animal's maintenance energy requirements and a second diet containing calories that do not meet the animal's maintenance energy requirements. In preferred embodiments, the described feeding pattern and diets are ted in conjunction with one or more weight loss agents.Type: ApplicationFiled: August 22, 2013Publication date: February 27, 2014Applicant: Nestec SAInventor: Yuanlong Pan
-
Patent number: 8653055Abstract: The invention provides novel compositions of water-insoluble corticosteroid drug in combination with antimicrobial agents and very low concentrations of polymers and surfactants for topical, otic and ophthalmic treatment. The invention provides stable aqueous suspension where the ingredients remain in such a state so as to allow for immediate re-suspension, when desired, even after extended periods of settling. The invention provides also a method for treating inflammation with low systemic absorption and side-effects of the corticosteroid.Type: GrantFiled: September 15, 2005Date of Patent: February 18, 2014Assignee: Teva Animal Health, Inc.Inventors: Richard K. Farng, Chung-Tsin Chiu, Ba Cuong Tu, Kenneth W. Kwochka
-
Publication number: 20140045806Abstract: Intravaginal DHEA is used for the treatment of at least one condition selected from the group consisting of female hypoactive sexual desire disorder, female sexual arousal disorder, female orgasm disorder and female sexual interest arousal disorder in a woman who either (1) is not suffering from symptoms of vulvo-vaginal atrophy and/or (2) is not suffering from moderate to severe dyspareunia.Type: ApplicationFiled: July 16, 2013Publication date: February 13, 2014Inventor: Fernand LABRIE
-
Publication number: 20140038930Abstract: Method of using an androgen, such as dehydroepiandrosterone (DHEA) or testosterone, to improve human folliculogenesis. The method includes measuring a baseline follicle stimulating hormone (FSH) level of the human female, and when the baseline FSH level is below about 40.0 mIU/ml, administering about 75 milligrams of the androgen per day to the female for at least four months to treat ovarian follicles in at least one ovary of the female to improve human folliculogenesis during the at least four months. The present invention further is directed to a method of restoring the ovarian environment of an older human female to that of a younger human female. The method includes administering about 75 milligrams of an androgen per day to the female for at least four months.Type: ApplicationFiled: June 28, 2013Publication date: February 6, 2014Inventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Patent number: 8642069Abstract: Viral upper respiratory tract infections, upper respiratory infections, and common colds can be effectively treated by the administration of a combination of a nasal steroid and a nasal antihistamine. By the administration of the combination of a nasal steroid and a nasal antihistamine with the onset of cold symptoms, the histamine cascade and the inflammatory response are impeded or eliminated, reducing the severity, duration, or frequency of the onset of cold symptoms. The combination of a nasal steroid and a nasal antihistamine may be, for example, a physical mixture of the steroid and antihistamine, or it may effectively be a combination wherein the patient is administered one component (either the steroid or the antihistamine) followed by the other, without physical mixing beforehand.Type: GrantFiled: August 27, 2009Date of Patent: February 4, 2014Inventor: Alexander D. Goldin
-
Patent number: 8637474Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in treating central nervous system disorders by over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of enhancing brain's cognitive function and reducing neuronal cell death in mammals and humans.Type: GrantFiled: January 5, 2012Date of Patent: January 28, 2014Assignee: The Hong Kong University of Science and TechnologyInventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
-
Publication number: 20140018338Abstract: Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.Type: ApplicationFiled: January 24, 2012Publication date: January 16, 2014Inventors: Kartik Chandran, Sean Whelan, Thijn Brummelkamp, Jan Carette, Matthijs Raaben
-
Publication number: 20140018339Abstract: Methods are provided for reducing chronic inflammatory pain, increasing the levels of endogenous opioid peptides, as well as increasing the pain threshold of a subject having symptoms of androgen deficiency, comprising transdermally administering a composition comprising a bioactive androgen on a daily basis. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject. The invention also encompasses administration of a composition consisting essentially of an androgen for the treatment of chronic inflammatory pain, and for increasing the pain-threshold in a subject.Type: ApplicationFiled: November 17, 2011Publication date: January 16, 2014Applicant: WHITE MOUNTAIN PHARMA, INC.Inventor: Hillary D. White
-
Publication number: 20140018751Abstract: The invention relates to pharmaceutical formulations, in particular to transdermal therapeutic systems, which are characterized in that little or no active ingredient crystallizes out at the interface between the removable protective film (release liner) and the active-ingredient-containing matrix.Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicant: Bayer Intellectual Property GmbHInventors: Stefan BRACHT, lldiko TEREBESI, Thomas LANGGUTH
-
Patent number: 8629130Abstract: A method of inhibiting growth of cancer cells comprising contacting cancer cells with a 6-substituted estradiol derivative in an amount at least partially sufficient to inhibit said growth is disclosed. The compounds have the general formula depicted below, herein R1, R2, R3, R4, R5, R6 and R7 are as defined herein.Type: GrantFiled: April 30, 2012Date of Patent: January 14, 2014Assignee: Endece, LLCInventor: James G. Yarger
-
Publication number: 20140011791Abstract: Methods for effective remyelination in patients are disclosed comprising treating the patient with an androgen receptor ligand which exerts binding to androgen receptors and elicits androgen-receptor-induced biological responses at a dosage sufficient to induce remyelination. The androgen compound preferably comprises MENT in an androgen targeting both androgen and estrogen receptors, and the methods include combining the androgen compound with a progestin compound in order to provide both contraception in men and treatment for neurodegeneration.Type: ApplicationFiled: March 22, 2012Publication date: January 9, 2014Applicant: THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Abdelmouman Ghoumari, Said Ghandour, Rashad Hussain, Bartosz Bielecki
-
Publication number: 20140011789Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.Type: ApplicationFiled: September 13, 2013Publication date: January 9, 2014Applicant: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides
-
Publication number: 20140011785Abstract: The present invention relates to antiandrogenic compounds which may be administered for the treatment of androgen excess in the skin and by way of consequence, the treatment of acne, baldness or hirsuitism in subject or patient.Type: ApplicationFiled: September 6, 2013Publication date: January 9, 2014Applicant: Yale UniversityInventor: Richard Hochberg
-
Publication number: 20140011787Abstract: Method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering an androgen, such as dehydroepiandrosterone or testosterone, to the female for at least about one month, and then evaluating a second anti-Müllerian hormone level of the female. Change in the anti-Müllerian hormone level is indicative of change in the ovarian reserve, e.g., when the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level, the ovarian reserve has improved. The androgen administration may continue until the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level by a desired percentage or amount.Type: ApplicationFiled: June 27, 2013Publication date: January 9, 2014Inventors: Norbert Gleicher, David H. Barad, Dwyn V. Harben
-
Publication number: 20140011788Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.Type: ApplicationFiled: August 13, 2013Publication date: January 9, 2014Inventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20130345149Abstract: Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.Type: ApplicationFiled: August 21, 2013Publication date: December 26, 2013Applicant: ALLERGAN, INC.Inventors: Kevin S. Warner, Ajay Parashar
-
Publication number: 20130344083Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.Type: ApplicationFiled: March 14, 2013Publication date: December 26, 2013Inventors: C. Wilson Xu, Yasuyo Urasaki
-
Publication number: 20130331365Abstract: The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).Type: ApplicationFiled: August 19, 2013Publication date: December 12, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Eva Y.H.P. Lee
-
Publication number: 20130324508Abstract: The present invention relates to a biomarker for characterizing prostate cancer and method of using the same. More particularly, the invention relates to method of using a membrane-associated C family G protein-coupled receptor GPRC6A as biomarker of characterizing prostate cancer progression. The present invention also provides a kit for detecting prostate cancer in a subject.Type: ApplicationFiled: June 3, 2013Publication date: December 5, 2013Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Leigh Darryl Quarles, Min Pi
-
Patent number: 8598149Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from a mental disorder amenable to treatment by mifepristone. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1300 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1300 ng/mL.Type: GrantFiled: August 27, 2008Date of Patent: December 3, 2013Assignee: Corcept Therapeutics, Inc.Inventor: Joseph K. Belanoff
-
Publication number: 20130317462Abstract: A transdermal delivery system comprising a composition comprising a pharmacological agent and a penetration enhancer wherein the penetration enhancer comprises polyethylene glycol (PEG) of average molecular weight no more than 300.Type: ApplicationFiled: May 6, 2013Publication date: November 28, 2013Applicant: Acrux DDS Pty Ltd.Inventors: Kerrie Setiawan, Adam Watkinson
-
Publication number: 20130316996Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.Type: ApplicationFiled: December 11, 2012Publication date: November 28, 2013Applicant: Acrux DDS Pty LtdInventor: Acrux DDS Pty Ltd
-
Publication number: 20130303501Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.Type: ApplicationFiled: July 15, 2013Publication date: November 14, 2013Inventors: Robert E. Dudley, Dominique Drouin
-
Publication number: 20130295166Abstract: The subject invention provides improved testosterone gel formulations.Type: ApplicationFiled: January 18, 2012Publication date: November 7, 2013Applicant: FERRING B.V.Inventors: Arnaud Grenier, Dario N. Carrara
-
Publication number: 20130287791Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Inventor: C. Wilson Xu
-
Publication number: 20130280330Abstract: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).Type: ApplicationFiled: July 30, 2010Publication date: October 24, 2013Applicant: XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD.Inventors: Renle Hu, Jiucheng Wang, Tao Chen, Hua Liang, Duohao Ding, Yaqi Jiao
-
Publication number: 20130281416Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.Type: ApplicationFiled: June 19, 2013Publication date: October 24, 2013Inventor: Robert J. GYURIK
-
Publication number: 20130266625Abstract: On one hand, the present invention relates to cosmetic compositions comprising poly(lactic glycolic)acid (PLGA) nanoparticles for applications to the skin. On the other hand, it also concerns polymeric nanoparticles having on its surface a plurality of cosmetically active agents, each of said agents being associated to said nanoparticle via oleylcysteineamide, delivery systems for topical application based on said particles and cosmetic formulations comprising said particles.Type: ApplicationFiled: January 24, 2012Publication date: October 10, 2013Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Simon Benita, Taher Nasser, Nour Karra, Amit Badihi
-
Publication number: 20130259920Abstract: A process for the preparation of a bioadhesive laminate comprising a hot-melt extruded reservoir layer and a hot-melt extruded backing layer is provided. The reservoir layer comprises a thermoplastic bioadhesive composition containing an active agent. An active agent-containing thermoplastic bioadhesive hydrophilic composition is hot-melt coextruded with a hydrophobic composition to form at least a bi-layered laminate. The hydrophilic composition and the hydrophobic composition have at least one polymer in common. In addition, the melt flow index of the hydrophobic composition is within 50% of the melt flow index of the hydrophilic composition. As a result, the laminate has a uniform transverse cross-section and/or a uniform longitudinal cross-section throughout a major of the length of the laminate. Moreover, when the laminate is divided into unit doses of approximately the same size, they have a high degree of content uniformity with respect to the active agent(s) present therein.Type: ApplicationFiled: May 28, 2013Publication date: October 3, 2013Inventors: Michael M. Crowley, Justin M. Keen, John J. Koleng, Feng Zhang
-
Patent number: 8541400Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: GrantFiled: August 4, 2005Date of Patent: September 24, 2013Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg